RxDoctor Payments Data

Baltej Dosanjh, MD

Family Medicine · Modesto, CANPI 1346536711

Payments from drug & device makers

$1,835in general payments, 2019–2025

Across 93 payments — averaging $19.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$595
  • GSK$200
  • Novo Nordisk$177
  • Lilly USA, LLC$157
  • Pfizer$83
  • Bayer$78
  • plus $545 from 15 others

What the payments were for

  • Food & beverage$1,79098%
  • Education$452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,835 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$33,190
Medicare patients
128
Services billed
271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide97$136,232
JardianceEmpagliflozin92$120,087
EliquisApixaban56$81,425
Trelegy ElliptaFluticasone/Umeclidin/Vilanter82$64,929
JanuviaSitagliptin Phosphate43$44,461
RybelsusSemaglutide27$39,748
RexultiBrexpiprazole11$29,196
TradjentaLinagliptin27$28,445
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen835$21,876
FarxigaDapagliflozin Propanediol19$21,155
Combivent RespimatIpratropium/Albuterol Sulfate28$18,656
XareltoRivaroxaban11$16,276
MounjaroTirzepatide14$15,222
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$14,469
JentaduetoLinagliptin/Metformin Hcl12$10,453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Jentadueto$62$177,641159 claims
Novo NordiskOzempic, Rybelsus$177$175,980124 claims
PfizerEliquis$83$81,42556 claims
GSKTrelegy Ellipta$200$64,92982 claims
MerckJanuvia$33$44,46143 claims
AstraZenecaFarxiga, Breztri Aerosphere$595$35,62432 claims
Otsuka America Pharmaceutical, Inc.Rexulti$70$29,19611 claims
Lilly USA, LLCMounjaro$157$15,22214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →